Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 1—January 2006
Dispatch

Novel Parvovirus and Related Variant in Human Plasma

Jacqueline F. Fryer*, Amit Kapoor†‡, Philip D. Minor*, Eric Delwart†‡, and Sally A. Baylis*Comments to Author 
Author affiliations: *National Institute for Biological Standards and Control, Hertfordshire, United Kingdom; †Blood Systems Research Institute, San Francisco, California, USA; ‡University of California, San Francisco, California, USA

Main Article

Figure 1

A) Specificity of primers for PARV4. Samples in lanes 1–5 were amplified by using primers directed to open reading frame 1 (ORF1) of PARV4. Template DNA in lane 1 was a plasmid subclone of the PARV4 ORF1 region. In lane 2, the template DNA was derived from parvovirus B19 International Standard (99/800, National Institute for Biological Standards and Control, South Mimms, UK) as representative of genotype 1 erythrovirus sequences; in lane 3, the template DNA was derived from a genotype 2 erythrov

Figure 1. A) Specificity of primers for PARV4. Samples in lanes 1–5 were amplified by using primers directed to open reading frame 1 (ORF1) of PARV4. Template DNA in lane 1 was a plasmid subclone of the PARV4 ORF1 region. In lane 2, the template DNA was derived from parvovirus B19 International Standard (99/800, National Institute for Biological Standards and Control, South Mimms, UK) as representative of genotype 1 erythrovirus sequences; in lane 3, the template DNA was derived from a genotype 2 erythrovirus plasmid clone (A6; obtained from K. Brown, National Heart, Lung and Blood Institute, Bethesda, MD, USA); in lane 4, the template DNA was derived from a genotype 3 erythrovirus plasmid clone (D91.1; obtained from A. Garbarg-Chenon, Hôpital Trousseau, Paris, France). Template DNA in the erythrovirus samples (lanes 2–4) was adjusted to give ≈105.5 copies of each genotype per reaction. Lane 5, no template control. Polymerase chain reaction (PCR) products were analyzed on a 2.5% agarose gel alongside PCR Markers (M) (Promega, Madison, WI, USA). B) Screening manufacturing plasma samples for PARV4. Samples in lanes 1–6 were amplified by using primers directed to the ORF1 region of PARV4. Template DNA in lanes 1 and 2 consisted of 1 × 102 and 1 × 103 copies of the ORF1 subclone of PARV4. In lane 3, the template DNA was derived from a plasma pool containing 3.9 × 106 PARV4 genome copies/mL plasma; in lane 4, the template DNA was derived from a plasma pool containing <500 PARV4 genome copies/mL plasma; in lane 5, the template DNA was derived from a plasma pool that tested negative for PARV4 sequences. Lane 6, no template control. PCR products were analyzed on a 2.5% agarose gel alongside PCR Markers (M) (Promega).

Main Article

Page created: February 21, 2012
Page updated: February 21, 2012
Page reviewed: February 21, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external